Kronos Bio, Inc. Company Profile

03:55 EDT 16th October 2018 | BioPortfolio

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research. For more information, please visit or follow the company on LinkedIn.

News Articles [21 Associated News Articles listed on BioPortfolio]

Kronos Bio raises $18mm in seed funding

Cancer drug discovery firm Kronos Bio Inc. raised $18mm in seed funding from Omega Funds, BellCo Capital, Vida Ventures, and individual investors/board members Norbert Bischofberger, PhD (Kronos' new ...

#news #biotech Gilead R&D chief Bischofberger looks to start over at Kronos Bio

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Gilead R&D chief Bischofberger looks to start over at Kronos Bio .Longti...

Former Gilead R&D Head Emerges as CEO of Startup Kronos Backed by Gilead Chairman

Two months after walking away from his role as head of R&D and chief scientific officer at Gilead Sciences, Norbert Bischofberger has re-emerged at the helm of startup Kronos Bio, Inc.

Former Gilead CSO Bischofberger Lands At Kronos As C-Suite Moves To Start-Ups Continue

Norbert Bischofberger returns to his start-up roots, exiting Gilead after nearly 30 years to become CEO of Kronos, which is...    

What's the Future of Healthcare Technology? Answers on the Next Workforce Institute Radio Podcast

Kronos: What:   Joyce Maroney, executive director ...

Gilead’s Norbert Bischofberger Named Kronos Bio CEO

Norbert Bischofberger has been named president and CEO of Kronos Bio. Bischofberger comes to the Cambridge, MA, cancer drug developer from Gilead Sciences (NASDAQ: GILD), where he was executive vice p...

AstraZeneca announces positive results from KRONOS phase III trial for PT010 triple combo therapy in moderate to very severe COOD

AstraZeneca announced publication of results from the KRONOS phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate...

Workforce technology to curb the major challenges faced by the services sector, says Kronos

Technologies that empower workers to do their jobs more effectively will be crucial in the battle for greater productivity and employee satisfaction Organisations operating within the services sector ...

Drugs and Medications [0 Results]


PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study.

Little is known regarding the progression of preclinical atherosclerosis upon cessation of menopausal hormone therapy (MHT). This study evaluated changes in carotid artery intima-media thickness (CIMT...

SLCO1B1 genetic variation and hormone therapy in menopausal women.

Response to menopausal hormone therapy (MHT) shows individual variation. SLCO1B1 encodes the OATP1B1 transporter expressed in the liver that transports many endogenous substances, including estrone su...

Solar reclamation of wastewater effluent polluted with bisphenols, phthalates and parabens by photocatalytic treatment with TiO/NaSO at pilot plant scale.

Investigations of anthropogenic contaminants in fresh- and wastewater have shown a wide variety of undesirable organic compounds such as Endocrine Disruptors (EDs). As a result, wastewater treatments ...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

KEEPS Cognitive and Affective Study

The KEEPS Cognitive and Affective Study is a multi-center clinical trial investigating the potential benefits of menopausal hormone therapies administered to perimenopausal women. The UW ...

TRIAGE-CRT Telemonitoring in Patients With CHF and Indication of CRT-D

This feasibility study will investigate the clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) and weight and blood pressure (BP) external telemonitoring (ETM) in the f...

KEEPS Mammographic Density And Breast Health Ancillary Study

Combined estrogen and progestin therapy has been shown to increase mammographic density and incidence of breast cancer in randomized trials. We propose to examine the effects of now common...

Companies [4 Associated Companies listed on BioPortfolio]

Kronos Incorporated


Kronos Optimal Health Company

Kronos Optimal Health Company is a leader in the science of healthy living. Our programs and services have been developed by leading physicians and researchers at Kronos Science Laboratories to addres...

Kronos Bio, Inc.

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research in...

Kronos Communicated Data Inc.

Formed in 1993 to take advantage of the technical advancements and business evolution brought about by emerging technologies, Kronos builds solutions solely for pharmaceutical and biotech research. In...

More Information about "Kronos Bio, Inc." on BioPortfolio

We have published hundreds of Kronos Bio, Inc. news stories on BioPortfolio along with dozens of Kronos Bio, Inc. Clinical Trials and PubMed Articles about Kronos Bio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kronos Bio, Inc. Companies in our database. You can also find out about relevant Kronos Bio, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record